Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis

Expert Review of Vaccines

Volumn 15, Issue 2, 2016, Pages 173-187

  Jorquera, Patricia A ^a   Anderson, Lydia ^a   Tripp, Ralph A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

biomarkers; disease; F protein; G protein; protection; RSV; vaccine

Indexed keywords

CX3C CHEMOKINE; CYTOKINE; GLYCINE DEHYDROGENASE (DECARBOXYLATING); GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN A; LEUKOTRIENE; MATRIX METALLOPROTEINASE; MICRORNA; NEUROTROPHIN; NEUTRALIZING ANTIBODY; PALIVIZUMAB; PROTEIN ANTIBODY; PROTEIN M2; RESPIRATORY SYNCYTIAL VIRUS F PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SH PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN; BIOLOGICAL MARKER;

AGED; ANTIBODY RESPONSE; CELLULAR IMMUNITY; COTTON RAT; FEMALE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; MOUSE MODEL; NONHUMAN; PREGNANT WOMAN; PRIMATE MODEL; PRIORITY JOURNAL; RAT MODEL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RUMINANT; T LYMPHOCYTE; VACCINATION; VACCINE PRODUCTION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; ANIMAL; BRONCHIOLITIS; DISEASE MODEL; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOGENICITY; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TRENDS; VIROLOGY;

ANIMALS; BIOMARKERS; BRONCHIOLITIS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84955691907     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1115353     Document Type: Review

References (139)

1. Harris J, Werling D. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol. 2003; 5: 671-680
2. Castilow EM, Meyerholz DK, Varga SM. Il-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol. 2008; 180: 2376-2384
3. Oshansky CM, Zhang W, Moore E., et al. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 2009; 4: 279-297
4. Polack FP. The changing landscape of respiratory syncytial virus. Vaccine. 2015. pii: S0264-410X(15)01072-5
5. Krishnamoorthy N, Khare A, Oriss TB., et al. Early infection with respiratory syncytial virus impairs regulatory t cell function and increases susceptibility to allergic asthma. Nat Med. 2012; 18: 1525-1530
6. Kiss G, Holl JM, Williams GM., et al. Structural analysis of respiratory syncytial virus reveals the position of m2-1 between the matrix protein and the ribonucleoprotein complex. J Virol. 2014; 88: 7602-7617
7. Guvenel AK, Chiu C, Openshaw PJ. Current concepts and progress in rsv vaccine development. Expert Rev Vaccines. 2014; 13: 333-344
8. Anderson LJ. Respiratory syncytial virus vaccine development. Semin Immunol. 2013; 25: 160-171
9. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev. 2011; 239: 149-166
10. Kurt-Jones EA, Popova L, Kwinn L., et al. Pattern recognition receptors tlr4 and cd14 mediate response to respiratory syncytial virus. Nat Immunol. 2000; 1: 398-401
11. Murawski MR, Bowen GN, Cerny AM., et al. Respiratory syncytial virus activates innate immunity through toll-like receptor 2. J Virol. 2009; 83: 1492-1500
12. Rallabhandi P, Phillips RL, Boukhvalova MS., et al. Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (tlr4) signaling is inhibited by the tlr4 antagonists rhodobacter sphaeroides lipopolysaccharide and eritoran (e5564) and requires direct interaction with md-2. MBio. 2012;3(4). pii: e00218-12
13. Lambert SL, Aslam S, Stillman E., et al. A novel respiratory syncytial virus (rsv) f subunit vaccine adjuvanted with gla-se elicits robust protective th1-Type humoral and cellular immunity in rodent models. PLoS One. 2015; 10: e0119509
14. Turner TM, Jones LP, Tompkins SM., et al. A novel influenza virus hemagglutinin-respiratory syncytial virus (rsv) fusion protein subunit vaccine against influenza and rsv. J Virol. 2013; 87: 10792-10804
15. McLellan JS, Chen M, Leung S., et al. Structure of rsv fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340: 1113-1117
16. McLellan JS, Yang Y, Graham BS., et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85: 7788-7796
17. Magro M, Andreu D, Gomez-Puertas P., et al. Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol. 2010; 84: 7970-7982
18. McLellan JS, Chen M, Joyce MG., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013; 342: 592-598
19. Liang B, Surman S, Amaro-Carambot E., et al. Enhanced neutralizing antibody response induced by respiratory syncytial virus pre-fusion f protein expressed by a vaccine candidate. J Virol. Forthcoming 2015. 10.1128/JVI.01373-15
20. Krarup A, Truan D, Furmanova-Hollenstein P., et al. A highly stable prefusion rsv f vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015; 6: 8143
21. Cheon IS, Shim BS, Park SM., et al. Development of safe and effective rsv vaccine by modified cd4 epitope in g protein core fragment (gcf). PLoS One. 2014; 9: e94269
22. McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol. 2013; 372: 83-104
23. Tripp RA, Jones LP, Haynes LM., et al. Cx3c chemokine mimicry by respiratory syncytial virus g glycoprotein. Nat Immunol. 2001; 2: 732-738
24. Griese M. Respiratory syncytial virus and pulmonary surfactant. Viral Immunol. 2002; 15: 357-363
25. Malhotra R, Ward M, Bright H., et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect. 2003; 5: 123-133
26. Ghildyal R, Hartley C, Varrasso A., et al. Surfactant protein a binds to the fusion glycoprotein of respiratory syncytial virus and neutralizes virion infectivity. J Infect Dis. 1999; 180: 2009-2013
27. Jorquera PA, Choi Y, Oakley KE., et al. Nanoparticle vaccines encompassing the respiratory syncytial virus (rsv) g protein cx3c chemokine motif induce robust immunity protecting from challenge and disease. PLoS One. 2013; 8: e74905
28. Schepens B, Schotsaert M, Saelens X. Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen. Immunotherapy. 2015; 7: 203-206
29. Lee YN, Hwang HS, Kim MC., et al. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (rsv) g protein confers protection against rsv without inflammatory disease. Virology. 2015; 476: 217-225
30. Gu H, Li T, Han L., et al. Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination. Hum Vaccin Immunother. 2015; 11: 1057-1064
31. Gan SW, Ng L, Lin X., et al. Structure and ion channel activity of the human respiratory syncytial virus (hrsv) small hydrophobic protein transmembrane domain. Protein Sci. 2008; 17: 813-820
32. Bueno SM, Gonzalez PA, Cautivo KM., et al. Protective t cell immunity against respiratory syncytial virus is efficiently induced by recombinant bcg. Proc Natl Acad Sci U S A. 2008; 105: 20822-20827
33. Cautivo KM, Bueno SM, Cortes CM., et al. Efficient lung recruitment of respiratory syncytial virus-specific th1 cells induced by recombinant bacillus calmette-guerin promotes virus clearance and protects from infection. J Immunol. 2010; 185: 7633-7645
34. Blodorn K, Hagglund S, Fix J., et al. Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (brsv) with deletion of the sh gene and subunit vaccines based on recombinant human rsv proteins: n-nanorings, p and m2-1, in calves with maternal antibodies. PLoS One. 2014; 9: e100392
35. Pierantoni A, Esposito ML, Ammendola V., et al. Mucosal delivery of a vectored rsv vaccine is safe and elicits protective immunity in rodents and nonhuman primates. Mol Ther Methods Clin Dev. 2015; 2: 15018
36. Demirjian A, Levy O. Safety and efficacy of neonatal vaccination. Eur J Immunol. 2009; 39: 36-46
37. Malloy AM, Falsey AR, Ruckwardt TJ. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol. 2013; 372: 211-231
38. Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric rsv vaccine. Hum Vaccin. 2009; 5: 582-591
39. Oliveira DB, Iwane MK, Prill MM., et al. Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis. J Clin Virol. 2015; 65: 26-31
40. Forbes ML, Kumar VR, Yogev R., et al. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Hum Vaccin Immunother. 2014; 10: 2789-2794
41. Chi H, Hsu CH, Chang JH., et al. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in taiwan. PLoS One. 2014; 9: e100981
42. Banerji A, Panzov V, Young M., et al. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in nunavut. Can Respir J. 2014; 21: 185-189
43. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine. 2003; 21: 3406-3412
44. Siegrist CA, Lambert PH. Maternal immunity and infant responses to immunization: factors influencing infant responses. Dev Biol Stand. 1998; 95: 133-139
45. Shinoff JJ, OBrien KL, Thumar B., et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis. 2008; 198: 1007-1015
46. Englund JA, Mbawuike IN, Hammill H., et al. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis. 1993; 168: 647-656
47. Adedinsewo DA, Noory L, Bednarczyk RA., et al. Impact of maternal characteristics on the effect of maternal influenza vaccination on fetal outcomes. Vaccine. 2013; 31: 5827-5833
48. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (tdap) immunization and protection of young infants. Clin Infect Dis. 2013; 56: 539-544
49. Chu HY, Englund JA. Maternal immunization. Clin Infect Dis. 2014; 59: 560-568
50. Chu HY, Steinhoff MC, Magaret A., et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in bangladesh. J Infect Dis. 2014; 210: 1582-1589
51. Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy? Curr Opin Infect Dis. 2015; 28: 221-224
52. Falsey AR, Hennessey PA, Formica MA., et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352: 1749-1759
53. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging. 2005; 22: 577-587
54. Ponnappan S, Ponnappan U. Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal. 2011; 14: 1551-1585
55. Falsey AR, Walsh EE, Capellan J., et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008; 198: 1317-1326
56. RSV: Transmission and prevention. [Internet]. Center for Disease Control and Prevention; 2014 [cited 2015 Nov 24]. Available from: http://www.cdc.gov/rsv/about/transmission.html
57. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47: 401-409
58. Chen RT, Markowitz LE, Albrecht P., et al. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990; 162: 1036-1042
59. Permar SR, Klumpp SA, Mansfield KG., et al. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis. 2004; 190: 998-1005
60. Permar SR, Klumpp SA, Mansfield KG., et al. Role of cd8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol. 2003; 77: 4396-4400
61. Polack FP, Lee SH, Permar S., et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med. 2000; 6: 776-781
62. Pan CH, Valsamakis A, Colella T., et al. Modulation of disease, t cell responses, and measles virus clearance in monkeys vaccinated with h-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A. 2005; 102: 11581-11588
63. Poste G. Bring on the biomarkers. Nature. 2011; 469: 156-157
64. Siber GR, Leszcynski J, Pena-Cruz V., et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis. 1992; 165: 456-463
65. Glenn GM, Smith G, Fries L., et al. Safety and immunogenicity of a sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013; 31: 524-532
66. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis. 2004; 189: 233-238
67. Caidi H, Harcourt JL, Tripp RA., et al. Combination therapy using monoclonal antibodies against respiratory syncytial virus (rsv) g glycoprotein protects from rsv disease in balb/c mice. PLoS One. 2012; 7: e51485
68. Miao C, Radu GU, Caidi H., et al. Treatment with respiratory syncytial virus g glycoprotein monoclonal antibody or f(ab)2 components mediates reduced pulmonary inflammation in mice. J Gen Virol. 2009; 90: 1119-1123
69. Collarini EJ, Lee FE, Foord O., et al. Potent high-Affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from b cells of infected patients. J Immunol. 2009; 183: 6338-6345
70. Choi Y, Mason CS, Jones LP., et al. Antibodies to the central conserved region of respiratory syncytial virus (rsv) g protein block rsv g protein cx3c-cx3cr1 binding and cross-neutralize rsv a and b strains. Viral Immunol. 2012; 25: 193-203
71. Zhang W, Choi Y, Haynes LM., et al. Vaccination to induce antibodies blocking the cx3c-cx3cr1 interaction of respiratory syncytial virus g protein reduces pulmonary inflammation and virus replication in mice. J Virol. 2010; 84: 1148-1157
72. Boyoglu-Barnum S, Gaston KA, Todd SO., et al. A respiratory syncytial virus (rsv) anti-g protein f(ab)2 monoclonal antibody suppresses mucous production and breathing effort in rsv ra2-line19f-infected balb/c mice. J Virol. 2013; 87: 10955-10967
73. Boyoglu-Barnum S, Todd SO, Chirkova T., et al. An anti-g protein monoclonal antibody treats rsv disease more effectively than an anti-f monoclonal antibody in balb/c mice. Virology. 2015; 483: 117-125
74. Haynes LM, Caidi H, Radu GU., et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (rsv) g protein mediates viral clearance and reduces the pathogenesis of rsv infection in balb/c mice. J Infect Dis. 2009; 200: 439-447
75. Radu GU, Caidi H, Miao C., et al. Prophylactic treatment with a g glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (rsv)-challenged naive and formalin-inactivated rsv-immunized balb/c mice. J Virol. 2010; 84: 9632-9636
76. Geskey JM, Thomas NJ, Brummel GL. Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (rsv). Biologics. 2007; 1: 33-43
77. Raghunandan R, Lu H, Zhou B., et al. An insect cell derived respiratory syncytial virus (rsv) f nanoparticle vaccine induces antigenic site ii antibodies and protects against rsv challenge in cotton rats by active and passive immunization. Vaccine. 2014; 32: 6485-6492
78. Smith G, Raghunandan R, Wu Y., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. 2012; 7: e50852
79. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004; 190: 373-378
80. Mills JT, Van Kirk JE, Wright PF., et al. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol. 1971; 107: 123-130
81. Habibi MS, Jozwik A, Makris S., et al. Impaired antibody-mediated protection and defective iga b-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015; 191: 1040-1049
82. Kim YI, DeVincenzo JP, Jones BG., et al. Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus. PLoS One. 2014; 9: e113100
83. Cherukuri A, Patton K, Gasser RA., et al. Adults 65 years old and older have reduced numbers of functional memory t cells to respiratory syncytial virus fusion protein. Clinical Vaccine Immunol: CVI. 2013; 20: 239-247
84. Lee FE-H, Walsh EE, Falsey AR., et al. The balance between influenza-And rsv-specific cd4 t cells secreting il-10 or ifnγ in young and healthy-elderly subjects. Mech Ageing Dev. 2005; 126: 1223-1229
85. Fulton RB, Weiss KA, Pewe LL., et al. Aged mice exhibit a severely diminished cd8 t cell response following respiratory syncytial virus infection. J Virol. 2013; 87: 12694-12700
86. Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev. 1999; 12: 298-309
87. Ha M, Kim VN. Regulation of microrna biogenesis. Nat Rev Mol Cell Biol. 2014; 15: 509-524
88. Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297
89. Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M., et al. Mirna biogenesis: biological impact in the development of cancer. Cancer Biol Ther. 2014; 15: 1444-1455
90. Inchley CS, Sonerud T, Fjaerli HO., et al. Nasal mucosal microrna expression in children with respiratory syncytial virus infection. BMC Infect Dis. 2015; 15: 150
91. Hirakawa S, Kojima T, Obata K., et al. Marked induction of matrix metalloproteinase-10 by respiratory syncytial virus infection in human nasal epithelial cells. J Med Virol. 2013; 85: 2141-2150
92. Yeo SJ, Yun YJ, Lyu MA., et al. Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch Virol. 2002; 147: 229-242
93. Dabo AJ, Cummins N, Eden E., et al. Matrix metalloproteinase 9 exerts antiviral activity against respiratory syncytial virus. PLoS One. 2015; 10: e0135970
94. Bont L, Heijnen CJ, Kavelaars A., et al. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis. 2001; 184: 355-358
95. Brand HK, Ferwerda G, Preijers F., et al. Cd4+ t-cell counts and interleukin-8 and ccl-5 plasma concentrations discriminate disease severity in children with rsv infection. Pediatr Res. 2013; 73: 187-193
96. Mella C, Suarez-Arrabal MC, Lopez S., et al. Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis. 2013; 207: 564-573
97. Brown PM, Schneeberger DL, Piedimonte G. Biomarkers of respiratory syncytial virus (rsv) infection: specific neurotrophin and cytokine levels provide increased accuracy in predicting disease severity. Paediatr Respir Rev. Paediatr Respir Rev. 2015 May 23. pii: S1526-0542(15)00038-X. 10.1016/j.prrv.2015.05.005
98. Khan N, Smith MT. Neurotrophins and neuropathic pain: role in pathobiology. Molecules. 2015; 20: 10657-10688
99. Zampieri N, Chao MV. Mechanisms of neurotrophin receptor signalling. Biochem Soc Trans. 2006 Aug;34(Pt 4):607-611
100. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1545-1564
101. Piedimonte G, Walton C, Samsell L. Vertical transmission of respiratory syncytial virus modulates pre-And postnatal innervation and reactivity of rat airways. PLoS One. 2013; 8: e61309
102. Tortorolo L, Langer A, Polidori G., et al. Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection. Am J Respir Crit Care Med. 2005; 172: 233-237
103. Matsuse H, Tsuchida T, Fukahori S., et al. Differential airway inflammatory responses in asthma exacerbations induced by respiratory syncytial virus and influenza virus a. Int Arch Allergy Immunol. 2013; 161: 378-382
104. Wedde-Beer K, Hu C, Rodriguez MM., et al. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol. 2002; 282: L1143-L1150
105. Tripp RA, Barskey A, Goss L., et al. Substance p receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. J Neuroimmunol. 2002; 129: 141-153
106. Tripp RA, Dakhama A, Jones LP., et al. The g glycoprotein of respiratory syncytial virus depresses respiratory rates through the cx3c motif and substance p. J Virol. 2003; 77: 6580-6584
107. Matsuse H, Hirose H, Tsuchida T., et al. Effects of respiratory syncytial virus infection on dendritic cells and cysteinyl leukotrienes in lung tissues of a murine model of asthma. Allergol Int Official J Jpn Soc Allergol. 2007; 56: 165-169
108. Kott KS, Salt BH, McDonald RJ., et al. Effect of secondhand cigarette smoke, rsv bronchiolitis and parental asthma on urinary cysteinyl lte4. Pediatr Pulmonol. 2008; 43: 760-766
109. Bem RA, Domachowske JB, Rosenberg HF. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol. 2011; 301: L148-L156
110. U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER); (CBER), C.f.B.E.a.R. Guidance for industry product development under the animal rule [Internet]. 2014 [cited 2015 Nov 11]. Available from http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf
111. Simoes EA, DeVincenzo JP, Boeckh M., et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis. 2015; 211 (Suppl 1): S1-S20
112. Sacco RE, Nonnecke BJ, Palmer MV., et al. Differential expression of cytokines in response to respiratory syncytial virus infection of calves with high or low circulating 25-hydroxyvitamin d3. PLoS One. 2012; 7: e33074
113. You D, Siefker DT, Shrestha B., et al. Building a better neonatal mouse model to understand infant respiratory syncytial virus disease. Respir Res. 2015; 16: 91
114. Cavallaro JJ, Maassab HF. Adaptation of respiratory syncytial (rs) virus to brain of suckling mice. Proc Soc Exp Biol Med. 1966; 121: 37-41
115. Kong X, Hellermann GR, Patton G., et al. An immunocompromised balb/c mouse model for respiratory syncytial virus infection. Virol J. 2005; 2: 3
116. Sacco RE, Durbin RK, Durbin JE. Animal models of respiratory syncytial virus infection and disease. Curr Opin Virol. 2015; 13: 117-122
117. Dreizin RS, Vyshnevetskaia LO, Bagdamian EE., et al. [Experimental rs virus infection of cotton rats. A viral and immunofluorescent study]. Vopr Virusol. 1971; 16: 670-676
118. Boukhvalova MS, Prince GA, Blanco JC. The cotton rat model of respiratory viral infections. Biologicals: J Int Assoc Biol Standardiz. 2009; 37: 152-159
119. Prince GA, Prieels JP, Slaoui M., et al. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (sigmodon hispidus). Lab Invest. 1999; 79: 1385-1392
120. Buchholz UJ, Granzow H, Schuldt K., et al. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (hrsv): effects on host range and evaluation as a live-Attenuated hrsv vaccine. J Virol. 2000; 74: 1187-1199
121. Elvander M, Vilcek S, Baule C., et al. Genetic and antigenic analysis of the g attachment protein of bovine respiratory syncytial virus strains. J Gen Virol. 1998; 79 (Pt 12): 2939-2946
122. Valarcher JF, Taylor G. Bovine respiratory syncytial virus infection. Vet Res. 2007; 38: 153-180
123. Rebelatto MC, Mead C, HogenEsch H. Lymphocyte populations and adhesion molecule expression in bovine tonsils. Vet Immunol Immunopathol. 2000; 73: 15-29
124. Casteleyn C, Breugelmans S, Simoens P., et al. The tonsils revisited: review of the anatomical localization and histological characteristics of the tonsils of domestic and laboratory animals. Clin Dev Immunol. 2011; 2011: 472460
125. Irvin CG, Bates JH. Measuring the lung function in the mouse: the challenge of size. Respir Res. 2003; 4: 4
126. Woolums AR, Anderson ML, Gunther RA., et al. Evaluation of severe disease induced by aerosol inoculation of calves with bovine respiratory syncytial virus. Am J Vet Res. 1999; 60: 473-480
127. Heidema J, Lukens MV, Van Maren WW., et al. Cd8+ t cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J Immunol. 2007; 179: 8410-8417
128. Gershwin LJ, Anderson ML, Wang C., et al. Assessment of ige response and cytokine gene expression in pulmonary efferent lymph collected after ovalbumin inhalation during experimental infection of calves with bovine respiratory syncytial virus. Am J Vet Res. 2011; 72: 134-145
129. Ackermann MR. Lamb model of respiratory syncytial virus-Associated lung disease: insights to pathogenesis and novel treatments. Ilar J. 2014; 55: 4-15
130. Gershwin LJ, Schelegle ES, Gunther RA., et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine. 1998; 16: 1225-1236
131. Meyerholz DK, Grubor B, Fach SJ., et al. Reduced clearance of respiratory syncytial virus infection in a preterm lamb model. Microbes Infect. 2004; 6: 1312-1319
132. Meyerholz DK, Gallup JM, Lazic T., et al. Pretreatment with recombinant human vascular endothelial growth factor reduces virus replication and inflammation in a perinatal lamb model of respiratory syncytial virus infection. Viral Immunol. 2007; 20: 188-196
133. Derscheid RJ, Gallup JM, Knudson CJ., et al. Effects of formalin-inactivated respiratory syncytial virus (fi-rsv) in the perinatal lamb model of rsv. PLoS One. 2013; 8: e81472
134. Blount RE Jr, Morris JA, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 1956; 92: 544-549
135. Collins PL, Whitehead SS, Bukreyev A., et al. Rational design of live-Attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res. 1999; 54: 423-451
136. Szentiks CA, Kondgen S, Silinski S., et al. Lethal pneumonia in a captive juvenile chimpanzee (pan troglodytes) due to human-Transmitted human respiratory syncytial virus (hrsv) and infection with streptococcus pneumoniae. J Med Primatol. 2009; 38: 236-240
137. Crowe JE Jr, Bui PT, Siber GR., et al. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (rsv) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when rsv antibodies are infused shortly before immunization. Vaccine. 1995; 13: 847-855
138. Hancock GE, Smith JD, Heers KM. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus. J Infect Dis. 2000; 181: 1768-1771
139. Schwarze J, ODonnell DR, Rohwedder A., et al. Latency and persistence of respiratory syncytial virus despite t cell immunity. Am J Respir Crit Care Med. 2004; 169: 801-805